EMA Withdrawn: Preotact (parathyroid hormone (rDNA)) — NPS Pharma Holdings Limited

View source ↗

Summary

EMA has withdrawn Preotact (parathyroid hormone rDNA) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Preotact (teriparatide)

Snippet

Status: Withdrawn. Therapeutic area: Osteoporosis, Postmenopausal. MAH: NPS Pharma Holdings Limited. Decision date: 16/05/2014